Grant C. Bogle

Insider Reports History

Location
Waltham, MA
Signature
/s/ Nathan McConarty, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Grant C. Bogle:

Company Role Class Num Shares Value Price $ Report Date Ownership
Nuvalent, Inc. Director Class A Common Stock 5,847 $437,121 $74.76 18 Jun 2025 Direct
Nuvalent, Inc. Director Stock Option (Right to Buy) 4,147 18 Jun 2025 Direct
Epizyme, Inc. President and CEO, Director Common Stock, par value $0.0001 0 $1.41 12 Aug 2022 Direct
Epizyme, Inc. President and CEO, Director Stock Option (Right to Buy) 0 09 Aug 2022 Direct

Insider Reports Filed by Grant C. Bogle

Symbol Company Period Transactions Value $ Form Type Role Filing Time
NUVL Nuvalent, Inc. 18 Jun 2025 2 $0 4 Director 20 Jun 2025, 16:33
NUVL Nuvalent, Inc. 05 Dec 2024 2 $0 4 Director 09 Dec 2024, 06:54
NUVL Nuvalent, Inc. 05 Dec 2024 0 $0 3 Director 09 Dec 2024, 06:53
/report/000089924322028851-bogle-grant-c-2022-08-12 Epizyme, Inc. 12 Aug 2022 2 $0 4 President and CEO, Director 16 Aug 2022, 18:52
/report/000089924322028421-bogle-grant-c-2022-08-09 Epizyme, Inc. 09 Aug 2022 6 +$106,241 4 President and Chief Executive Officer, Director 11 Aug 2022, 21:00
/report/000089924322011729-bogle-grant-c-2022-03-17 Epizyme, Inc. 17 Mar 2022 1 $0 4 President and Chief Executive Officer, Director 21 Mar 2022, 18:06
/report/000089924322004828-bogle-grant-c-2022-02-02 Epizyme, Inc. 02 Feb 2022 2 $0 4 President and Chief Executive Officer, Director 04 Feb 2022, 15:15
/report/000089924321033401-bogle-grant-c-2021-08-16 Epizyme, Inc. 16 Aug 2021 2 $0 4 President and Chief Executive Officer, Director 18 Aug 2021, 08:02
/report/000089924321023877-bogle-grant-c-2021-06-11 Epizyme, Inc. 11 Jun 2021 2 $0 4 Director 15 Jun 2021, 16:40